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A commentary on
Electronic cigarettes
by Grana RA, Ling PA, Benowitz N, Glantz S. Circulation (2015) 129:e490–2. doi: 10.1161/CIRCU-
LATIONAHA.114.008545
Electronic cigarettes were originally introduced as devices to facilitate smoking cessation, but
their efficacy in this regard has not been established. Instead, they are often used to facilitate
continued cigarette smoking in adults, and are common entry devices for nicotine dependency in
children and adolescents (1). The aim of this commentary is to emphasize these problems since far
from improving health, E-cigarettes may paradoxically be damaging physical/psychological health.
Furthermore, while this is certainly an issue for active smokers, itmay become an increasing problem
for those who are “passively vaping” E-cigarettes.
E-cigarettes are battery-operated devices, which deliver hits of nicotine via the inhalation of an
aerosol spray, which contains a mixture of nicotine, flavorings, and other chemicals (1–3). The
E-cigarette was originally introduced as an aid to facilitate smoking cessation. It followed the
successful development of earlier nicotine substitution devices, such as nicotine chewing gum, nico-
tine transdermal patch, and the inhaler (4–6). However, these earlier products were only partially
effective at nicotine delivery, with 2mg gum producing around 25% of the psychophysiological
effects of a nicotine cigarette and 4mg nicotine gum producing around 40% of its physiological
effects (7). Yet, despite their comparative inefficacy at nicotine delivery, they partially assuaged
nicotine cravings, which allowed them to double the success rates for smoking cessation (4).
Crucially, this was achieved without making these early nicotine substitution devices attractive to
non-smokers.
E-cigarettes were consciously designed to make them attractive, but unfortunately this can now
be seen as a mistake since it has encouraged their use as a facilitator for continued smoking
in adults, and has introduced many youngsters into nicotine and nicotine dependency. Grana
et al. (1) note that they were designed to look like cigarettes; also they were given “kid-friendly
flavors, including grape, chocolate, bubble gum, and gummy bear”; furthermore, they have also
been marketed “aggressively” often using simplistic and misleading messages. Since first introduced
into the USA and Europe in 2006, their usage has risen dramatically, with sales doubling every
year [Wells Fargo Internet report cited in Ref. (3)] so that instead of being used to aid tobacco
cessation, they are often being used to facilitate continued cigarette smoking. Grana et al. (1)
noted that many adult smokers continue to smoke tobacco in private, but vape E-cigarettes where
smoking is banned. Furthermore, E-cigarettes are providing a simple introduction into nicotine
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TABLE 1 | The adverse effects of nicotine dependency in cigarette smokers,
and the similar psychobiological problems predicted for E-cigarette users.
Mood fluctuation: smokers typically experience positive moods on smoking,
followed by negative moods on nicotine withdrawal. This mood vacillation is rapid,
with moods going up and down every day in parallel with cigarette/nicotine intake
(9, 11). Similar types of mood fluctuation are likely to be found in regular
E-cigarette “vapers”
Psychophysiological vacillation: the repetitive mood changes of smokers are just
one element of a core psychobiological fluctuation. Hence, alertness goes up and
down over the day, in parallel with the changes in mood state. Cognitive skills and
memory abilities may also fluctuate (13). Similar core psychobiological fluctuations
may also develop with E-cigarette users
Addiction potential: psychobiological fluctuation provides an essential rationale for
nicotine’s strong addiction potential. Similar basic processes underlie the
addiction potential of cocaine (10) and other CNS stimulants, such as
methamphetamine, MDMA, and mephedrone (8). To the extent that E-cigarettes
are effective at nicotine delivery – they will also show addiction potential
Wider psychobiological problems: nicotine dependency in cigarette smokers
leads to greater daily stress, depression, cognitive deficits, worse memory, poorer
sleep, lower self-efficacy, and many other deficits (12–15). Similar
psychobiological problems are predicted to develop in regular uses of E-cigarettes
dependency for children and adolescents. Grana et al. (1) reported
that youth use of E-cigarettes had increased from 3.3% in 2011 to
6.8% in 2012. They further noted that around a third of adolescent
E-cigarette users have never smoked a tobacco cigarette. Hence,
another major concern is the potential progression to higher
self-dosing with nicotine – readily achieved by progressing onto
cigarette smoking.
Grana et al. (1) noted several of health problems associated
with E-cigarettes: the noxious cancerous chemicals in the aerosol
vapors, the dangers of passive vaping (viz: as with passive cigarette
smoking), and several other problems. However, they did not
describe one of the most important problems – that nicotine
is highly addictive drug, and that regular nicotine usage has
many damaging psychological consequences. In neuropsychobi-
ological terms, nicotine is a powerful CNS stimulant, with many
basic similarities to other CNS stimulants, such as cocaine and
methamphetamine. Hence, the acute effects of increased heart
rate, greater alertness, and mood intensity are similar to every
other CNS stimulant drug. All drugs in this class generate brief
mood gains, but they are soon followed by negativemoods (feeling
tired and stressed), during the post-drug recovery period [for
review, see Ref. (8)]. With nicotine, this mood fluctuation can
be very rapid, with moods fluctuating up and down in paral-
lel with their nicotine intake [viz: every 20–30min in regular
smokers; see Figure 1 in Ref. (9)]. This rapid mood fluctua-
tion helps explain its high addiction potential. Indeed, nico-
tine is one of the most addictive of all drugs due to its very
rapid onset and consequent downturn. Hence, nicotine is similar
to cocaine in its psychobiological effects and addiction profile
(10). Furthermore, as with every CNS stimulant drug, nicotine
can damage the integrity of the HPA axis. Hence, all stimulant
drugs can lead to deficits in homeostasis, with disrupted sleep,
disrupted circadian rhythms, altered cortisol levels, and other
neurohormonal deficits [for review, see Ref. (8)]. Regular nico-
tine users can also suffer from neurocognitive and other psy-
chobiological deficits, which I have outlined in earlier reviews
(11, 12). These included daily mood fluctuation, increased stress,
heightened depression, poorer memory, and neuroimaging data
indicative of other neurocognitive deficits (6, 13–15). Finally,
these psychobiological problems tend to be greater in disadvan-
taged individuals with a propensity for distress, making nico-
tine and other stimulant drugs particularly damaging vulnerable
individuals (12).
In summary, nicotine is a powerful CNS stimulant with a
wide range of adverse effects. Its addictive potential may be
widely recognized, but there is far less realization about its
damaging psychobiological and health effects – on heart rate,
mood stability, alertness, neurocognitive skills, sleep, the HPA
axis, cortisol, and stress (12). These psychobiological deficits are
likely to be found in regular users of E-cigarettes, even in those
who use them alone (i.e., without smoking tobacco cigarettes
in parallel; see Table 1). The main aim of this commentary
is to emphasize that all these core functions, which are cru-
cial for human well-being, need to be empirically studied in
E-cigarette users.My core prediction is that these damaging effects
of nicotine in cigarette smokers will be replicated in users of
E-cigarettes.
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